$EBS Emergent BioSolutions has closed a five-year agreement with $JNJ Johnson &amp; Johnson unit Janssen Pharmaceuticals for large-scale drug substance manufacturing for J&amp;J's SARS-CoV-2 vaccine, Ad26.COV2-S.